- Location
Sunitinib
"-
Elderly Kidney Cancer Patients Benefit From Sunitinib Therapy
Feb 27, 2014By Sara Freeman, medwireNews Reporter Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows. Median progression-free survival ...
Tags: PFS, mRCC, Advanced Age, IFN
-
Patients with Advanced Renal Cell Carcinoma Are on and off Treatment
Feb 27, 2014By Sara Freeman, medwireNews Reporter mewireNews: Shortening the time that patients with advanced renal cell carcinoma are on and off treatment with sunitinib improves the drug’s overall tolerability without affecting its efficacy, ...
Tags: ORR, Tolerability, PFS, Sunitinib
-
The Patent Application Covers Synta's Proprietary HDC Technology
Nov 4, 2013Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...
-
Bayer HealthCare Submitted Submitted NDA
Dec 4, 2012Bayer HealthCare has submitted has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its regorafenib drug. The oral multi-kinase inhibitor regorafenib is used for the treatment of metastatic and ...
Tags: NDA, FDA, inhibitor, metastatic, GIST
Related Products
-
Manufacturer Supply Pharmaceutical Intermediate API Sunitinib CAS 557795-19-4
-
Sonwu Supply Purity Sunitinib Malate Powder Sunitinib Malate
-
CAS 341031-54-7 Sunitinib Malate Pharmaceutical Raw Material
-
Safe Delivery and Customs Clearance 99% Assay Chemical Powder Pharmaceutical Intermediate Sunitinib Malate CAS341031-54-7 with Superior Quality Sunitinib Malate
-
Sunitinib Malate 341031-54-7
-
99% Chemical Powder Pharmaceutical Intermediate Sunitinib Malate CAS 341031-54-7
